Antibody Manufacturing Xchange - Boston - 2026

What issues are you faced with when developing high concentration formulations for novel modalities? ...

What level of glycan shift is considered clinically meaningful after pivotal trials, and how should ...

What criteria are used to select buffers/additives during mAb purification?  Are they driven by proc ...

Therapeutic antibody modalities continue to advance, as do the needs for reliable sourcing and timel ...

How are you breaking down silos between cell line development, media strategy, and process developme ...

How are emerging therapeutic modalities (e.g., bispecifics, fusion proteins, non-mAbs) reshaping the ...

What study setup and design considerations should be taken into account, including understanding the ...

What are the real ceilings of codon design? From coding sequence optimization to full transcript des ...

What aspects of a process can be established prior to clone selection or stability?  How early can w ...

IDT Biologika is a biopharmaceutical contract development and manufacturing organization with more t ...

Traditional fed-batch processes have traditionally relied on scale-up to increase production, introd ...

Given its inherent time and resource demands, variability in productivity, and the rising complexity ...

How can optimized chromatographic techniques such as SEC or IEX be employed to effectively distingui ...

How can we ensure consistency in genetic integrity when implementing updated or intensified processe ...

How can we meet the growing demand for early developability assessment across expanding pipelines? W ...

Biopharma innovators face increasing pressure to advance biologic drug candidates to IND rapidly wit ...

What attributes make multispecific antibodies a promising emerging class of therapeutic modalities? ...

Cell culture media development for antibody production is beginning to incorporate artificial intell ...